ArticleJournal of nanobiotechnology2020
Bismuth chelate as a contrast agent for X-ray computed tomography.
Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Contrast Agents for Enhanced Bioimaging: A Comprehensive Review.Chembiochem : a European journal of chemical biology · 2026Review
- Radiotherapy-chemodynamic cancer therapy using bismuth-based nanoparticles: a synergistic approach for enhanced cancer treatment.RSC advances · 2025Review
- Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer.Small science · 2025Review
- Ultrasmall Bi/BiNanoscale advances · 2025Article
- Article
- Multifunctional Poly(Acrylic Acid)-Coated EuBiGdInternational journal of nanomedicine · 2025Article
- Toward the clinical translation of safe intravenous long circulating ILNEs contrast agent for CT imaging.Theranostics · 2025Article
- Spectral Photon-Counting Computed Tomography: Technical Principles and Applications in the Assessment of Cardiovascular Diseases.Journal of clinical medicine · 2024Review
- Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics.Theranostics · 2024Review
- Bi-HPDO3A as a novel contrast agent for X-ray computed tomography.Scientific reports · 2023Article
- [New contrast agents for photon-counting computed tomography].Radiologie (Heidelberg, Germany) · 2023Review
- Advances in nanomaterials for the diagnosis and treatment of head and neck cancers: A review.Bioactive materials · 2023Article
- Dual-Source Photon-Counting Computed Tomography-Part I: Clinical Overview of Cardiac CT and Coronary CT Angiography Applications.Journal of clinical medicine · 2023Review
- Computed Tomography of Cartilage: An Exploration of Novel Cationic Bismuth Contrast Agent.Annals of biomedical engineering · 2023Article
- Evaluating Hydroxyapatite, Gold Nanoparticles, and Graphene-Copper as Bimodal Agents for X-ray and Computed Tomography.Bioengineering (Basel, Switzerland) · 2023Article
- One stone, many birds: Recent advances in functional nanogels for cancer nanotheranostics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Biocompatible carbonized iodine-doped dots for contrast-enhanced CT imaging.Biomaterials research · 2022Article
- Facile Fabrication of BiFNanoscale research letters · 2021Article
- Advances in nanoprobes for molecular MRI of Alzheimer's disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundsDue to the unexpected side effects of the iodinated contrast agents, novel contrast agents for X-ray computed tomography (CT) imaging are urgently needed. Nanoparticles made by heavy metal elements are often employed, such as gold and bismuth. These nanoparticles have the advantages of long in vivo circulation time and tumor targeted ability. However, due to the long residence time in vivo, these nanoparticles may bring unexpected toxicity and, the preparation methods of these nanoparticles are complicated and time-consuming.
methodsIn this investigation, a small molecular bismuth chelate using diethylenetriaminepentaacetic acid (DPTA) as the chelating agent was proposed to be an ideal CT contrast agent.
resultsThe preparation method is easy and cost-effective. Moreover, the bismuth agent show better CT imaging for kidney than iohexol in the aspect of improved CT values. Up to 500 µM, the bismuth agent show negligible toxicity to L02 cells and negligible hemolysis. And, the bismuth agent did not induce detectable morphology changes to the main organs of the mice after intravenously repeated administration at a high dose of 250 mg/kg. The pharmacokinetics of the bismuth agent follows the first-order elimination kinetics and, it has a short half-life time of 0.602 h. The rapid clearance from the body promised its excellent biocompatibility.
conclusionsThis bismuth agent may serve as a potential candidate for developing novel contrast agent for CT imaging in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.